Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria
Authors:
Open Access
- 21 March 2024
- journal article
- research article
- Published by Taylor & Francis in Hematology
- Vol. 29 (1) , 2329030
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder characterized by the premature breakdown of red blood cells due to the ineffective inhibition of complement, a central part of the...Keywords
This publication has 42 references indexed in Scilit:
- Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient PopulationsAdvances in Therapy, 2023
- Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfallsSeminars in Immunology, 2022
- Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel methodResearch and Practice in Thrombosis and Haemostasis, 2020
- C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumabAmerican Journal of Hematology, 2020
- Paroxysmal nocturnal haemoglobinuriaNature Reviews Disease Primers, 2017
- Follow-up intervals in patients with Cushing’s disease: recommendations from a panel of experienced pituitary cliniciansPituitary, 2017
- Clinical Practice Guidelines From the AABBJAMA, 2016
- Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomenaInternational Journal of Hematology, 2011
- Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factorsThe Lancet, 1996
- Validity of Criteria Used for Detecting Underuse of Coronary RevascularizationJAMA, 1995